Home » Newsletters » BioWorld

BioWorld

Dec. 4, 1992

View Archived Issues

NUCLEOTIDE ANALOG SHOWS ANTI-CMV ACTIVITY

LIGAND UNDERWRITERS EXERCISE OPTION

RAC APPROVES CF TRIAL PROTOCOLS

SANDOZ, SCRIPPS SIGN $300 MILLION DEAL

SMITHKLINE INVESTS IN THERATECH

ROBERTSON STEPHENS CONFERENCE

LIPOSOME CO. OFFERS DEPOSITARY SHARES

ENZON, CREATIVE BIOMOLECULES TO NEGOTIATE

EMISPHERE TO RECEIVE PAYMENT

FOR CF THERAPY, INHALE

MARYLAND RESEARCH CENTER THINKS BIG

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 10, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...